The CD133+ cell as an advanced medicinal product for myocardial and limb ischemia

Cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. The aim of this review is to summarize available experimental and clinical data on CD133+ cells in the context of myocardial and peripheral ischemia, as well as to focus on the development of the CD133+ cell as an anti-ischemic AMP.